Athenex Announces the Addition of Simon Pedder, PhD and Raymond Yeung, MSc, MBA to its Global Leadership Team

Buffalo, NY and Hong Kong – Athenex, Inc. announced today that Simon Pedder, PhD, has joined Athenex as Vice President of Corporate Strategy and Business Development based in the U.S. and Mr. Raymond Yeung, MSc, MBA has joined as Senior Director and Deputy Head of Clinical Research and Regulatory Affairs, Asia-Pacific, based in Hong Kong.   Dr. Pedder…

Athenex Announces US FDA Allowance of the Investigational New Drug Application of Oradoxel, the Proprietary Oral Form of Docetaxel

Buffalo, NY and Hong Kong- Athenex, Inc. announced today that it has received United States Food and Drug Administration (US FDA) allowance to proceed in the clinic with its proprietary oral form of Docetaxel. This allowance to proceed represents Athenex’s sixth successful oncology investigational new drug (IND) application by the US FDA (5 oral anticancer…

Athenex Announces Progress in Registration Studies of Oral Oncology Drug and China Approvals of Symptom Therapeutic Products

Buffalo, NY and Hong Kong – Athenex, Inc. announced today several significant developments in its proprietary product pipeline within each of its three innovative platforms: Oral Absorption, Kinase Inhibitors and Symptom Therapeutics.   Oral Absorption Platform A pivotal registration study has commenced in the fourth quarter 2015 for Oraxol, the proprietary oral capsule formulation of…

Athenex Announces Recent Business Developments Including the Acquisition of Comprehensive Drug Enterprises

Buffalo, NY and Hong Kong– Athenex, Inc. announces the closing of the acquisition of Comprehensive Drug Enterprises (CDE) based in Hong Kong’s Science Park in a stock for stock transaction closed in July. The CDE platform includes a formulation research and development team based in Hong Kong and a Chongqing manufacturing plant in the Fengdu…

Athenex Completes Public/Private Partnership Agreement with Chongqing, China To Construct Two New Pharmaceutical Manufacturing Plants

Athenex announced today the completion and execution of a definitive agreement with the Banan District in Chongqing, China to construct two separate pharmaceutical manufacturing plants on Banan sites already identified and selected by Athenex management. Under the terms of the agreement, Banan will provide the funding for the land and construction of the manufacturing plants according to Athenex specifications, and Athenex will equip the facilities.

Hanmi Pharmaceuticals to Assign the Rights of the Indian Territory to Kinex as Part of the Orascovery Program Strategic Plan

Kinex Pharmaceuticals and Hanmi Pharmaceutical Co., Ltd. are pleased to announce the execution of an agreement for Kinex Pharmaceuticals to lead the development of the Orascovery program in India. The addition of this territory is part of the strategic plan to support Kinex and Hanmi’s joint effort to execute a global regulatory strategy. This also strengthens the existing agreement forged with Hanmi in December of 2011. With this agreement, Hanmi has granted to Kinex Pharmaceuticals the rights to develop and commercialize all products derived from the Orascovery program for all indications globally apart from Korea and Japan.

Kinex Pharmaceuticals Licenses Patents from Hong Kong Polytechnic University

Hong Kong Feb 13, 2015 – Kinex Pharmaceuticals today announces the exclusive licensing of global rights of three patents from The Hong Kong Polytechnic University and McGill University. These three patents covered the inventions by Professor Larry Chow and Professor William Chan including novel new chemical compounds that have nanomolar potency against a molecular target named Breast Cancer Resistance Protein (BCRP). BCRP is a protein pump known to pump drugs, including anticancer drugs, from cancer cells that can lead to drug resistance; and also to pump drugs back into gastrointestinal tract, which prevent some useful drugs to be delivered to their target.